Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Stock Movements, Quarterly Dividends and Product Recall News - Research Report on Pfizer, Johnson & Johnson, Bristol-Myers,



Stock Movements, Quarterly Dividends and Product Recall News - Research Report
        on Pfizer, Johnson & Johnson, Bristol-Myers, Merck, and Abbvie

PR Newswire

NEW YORK, September 24, 2013

NEW YORK, September 24, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Pfizer
Inc. (NYSE: PFE), Johnson & Johnson (NYSE: JNJ), Bristol-Myers Squibb Company
(NYSE: BMY), Merck & Co. Inc. (NYSE: MRK) and AbbVie Inc. (NYSE: ABBV).
Today's readers may access these reports free of charge - including full price
targets, industry analysis and analyst ratings - via the links below.

Pfizer Inc. Research Report

On September 19, 2013, Pfizer Inc. (Pfizer)'s stock declined 0.7% to end the
day at $28.84, compared to the previous day's closing price of $29.04. During
the day, the price fluctuated between $28.65 and $29.15. On the previous day,
September 18, 2013, the stock touched a high of $29.27, the highest reached in
over a month. The Full Research Report on Pfizer Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.analystscorner.com/r/full_research_report/d702_PFE]

--

Johnson & Johnson Research Report

On September 12, 2013, The New York Times published a report which stated that
Johnson & Johnson (J&J) has announced two recalls of well-known products in
the gap of a week. As per the report, the Company's pharmaceutical unit,
Janssen, informed doctors and patients on September 11, 2013 that it was
recalling one lot of Risperdal Consta, an injectable antipsychotic treatment,
after routine testing turned up evidence of mold; while last week, J&J
recalled 200,000 bottles of liquid Motrin for infants due to the speculations
of it containing tiny particles of plastic. The report mentioned that in both
cases, the recalls involved products or ingredients that were made by external
companies and the risk to patients was low. The Full Research Report on
Johnson & Johnson - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/07a8_JNJ]

--

Bristol-Myers Squibb Company Research Report

On September 19, 2013, Bristol-Myers Squibb Company (Bristol Myers)'s stock
rose 2.2%, from its previous day's closing of $46.52. The days' closing price
of $47.53 has been the Company's highest in over 3 months. Also, during the
day, the stock fluctuated from $46.38 to $47.58. The Full Research Report on
Bristol-Myers Squibb Company - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/81a9_BMY]

--

Merck & Co. Inc. Research Report

On September 19, 2013, Merck & Co. Inc. (Merck)'s stock declined 0.3% to
$48.26, from its previous day's closing price of $48.40. The stock fluctuated
from $48.10 to $48.49. The broad market index, S&P 500 also declined 0.2%
during the day. The Full Research Report on Merck & Co. Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.analystscorner.com/r/full_research_report/430d_MRK]

--

AbbVie Inc. Research Report

On September 19, 2013, AbbVie Inc. (AbbVie) announced that its Board of
Directors has authorized a quarterly cash dividend in the amount of $0.40 per
share. AbbVie informed that the cash dividend is payable on November 15, 2013
to stockholders of record at the close of the business on October 15, 2013.
The Full Research Report on AbbVie Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.analystscorner.com/r/full_research_report/273c_ABBV]

----

EDITOR NOTES:

 1. This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
 2. Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
 3. This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
 4. If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
 5. For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
 6. Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

SOURCE Analysts' Corner

Contact: Joe Thomas : +1-310-496-8071 (North America)
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement